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ABSTRACT
Objective: The aim of the study was to assess and compare the gelatinase activity and pellicle formation in extended-spectrum beta-lactamase (ESBL) 
and non-ESBL producing Acinetobacter baumannii isolates from diabetic foot ulcer infection (DFI).
Methods: A total of 42 isolates of A. baumannii recovered from patients of DFI from September 2016 to February 2018. Isolates were identified 
by the standard microbiological method and confirmed by the BD Phoenix 100 system. The antimicrobial susceptibility test was performed by the 
Kirby–Bauer disk diffusion method and ESBL was detected by double disk diffusion synergy test method. Gelatinase production was determined by 
the Luria Bertani agar supplemented with 30 g/L gelatin, and pellicle formation was determined by the Mueller-Hinton broth which is incubated at 
two different temperatures.
Results: A total of 42 A. baumannii isolates were multidrug resistant. Among 21 isolates, each was ESBL and non-ESBL producers. Pellicle formation 
at 25°C in ESBL and non-ESBL producer isolates was 47.61% (10/21) and 28.57% (06/21). Pellicle formation at 37°C in ESBL and non-ESBL producer 
isolates was 57.14% (12/21) and 42.85% (09/21), respectively. Gelatinase production was present in 38.09% ESBL and 28.57% in non-ESBL 
producers. ESBL strains were more virulent compared to non-ESBL producers among patients of DFIs.
Conclusion: This study showed that pellicle formation at 37°C was highly virulent due to ESBL producers. Gelatinase production was elevated in ESBL 
compared to non-ESBL producer isolates. This attribute of the isolates could render ESBL positive more pathogenic. Colistin and polymyxin B are the 
only choices of treatment for multidrug-resistant Acinetobacter baumannii infections.
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INTRODUCTION
Acinetobacter baumannii is a Gram-negative Coccobacillus that causes 
nosocomial infections such as urinary tract infections, respiratory 
infections, bacteremia, secondary meningitis, and wound infections in 
immunodeficiency individuals including diabetic patients [1].
Among diabetic foot ulcer infection (DFI) and 14.28% A. baumannii were 
found symptomatic with necrotizing fasciitis, osteomyelitis, pus discharge, 
leukocytosis, and low immune, so it can be considered as pathogen not to 
be colonizer due to the threatening of limb amputation [2,3]. A. baumannii 
is the second most commonly found pathogen among non-fermented 
bacteria in DFIs. Peripheral arterial diseases are often present in patients 
of DFIs and may lead to the poor penetration of antibiotics into the lower-
limb tissues, and thereby, this promotes grown of resistant bacteria [4]. 
Few virulence factors of A. baumannii have been recognized; these are 
biofilm formation, siderophore production, cell surface hydrophobicity, 
gelatinase production, and pellicle formation. Gelatinase is a protease 
enzyme produced by bacteria in ulcers/wound lead to break down 
the collagen in subcutaneous tissue, casein, hemoglobin, and other 
bioactive peptides and also are involved in inflammation, and contribute 
to virulence [5]. Pellicle formation in A. baumannii allows them to 
survive on less or nutrient-limited surfaces for several days [6]. The 
pellicle formation needs different proteins that are associated with pili 
formation such as chaperone-usher system pili and the putative type III 
pili [7]. The matrix of A. baumannii pellicles is complex, containing 
different extracellular polymeric substances, that is lipopolysaccharide, 
exopolysaccharides, and cell surface appendages that may be contributing 
factors for the occurrence and prevalence of A. baumannii in the 
clinical environment which exhibits different cell properties in wound/
ulcers [8]. In the hospital ward environment, pellicles could be formed 
in small droplets, and therefore, may involve in bacterial colonization to 
pathogenic for immunodeficiency or diabetic foot ulcer patients. Bacterial 
bunch may eventually be detached from the pellicle and move freely to 
cause infection [9]. Pellicle formation is more readily formed at 25°C and 
37°C. Bacteria in the pellicle could revert to the abiotic surface and cause 
infection. Due to this reason, hospital ward disinfectants and antiseptics 
should target this biofilm structure and protect bacteria from external 
hazards [6]. Such variations and differences could pose a challenge in the 
development of strategies that counter biofilm formation as a convenient 
and general therapeutic target to treat A. baumannii infections in patients 
of diabetic foot ulcer. This study was conducted to understand the 
virulence factors of the ESBL, non-ESBL producers, pellicle formation, and 
gelatinase production by A. baumannii in DFI patients, which may lead to 
the development of secondary infections and non-healing ulcer and lead 
to amputation of lower limb extremities. The purpose of the study was to 
assess and compare the gelatinase activity and pellicle formation in ESBL 
and non-ESBL producing A. baumannii isolates from DFI.
METHODS
A prospective 1-year study was carried out in the Department of General 
Surgery, Microbiology, and Yenepoya Research Center, Yenepoya Medical 
College, Mangalore, India. A total of 42 non-duplicate ESBL and non-ESBL 
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producing A. baumannii isolates were collected from September 2016 
to September 2017 after obtaining Ethical Clearance from Institutional 
Ethics Committee (Reg.No.- YU172/2016). A. baumannii was identified 
using standard methods based on Gram staining, cultured on 5% sheep 
blood, and MacConkey agar media, and identification was done using 
the BD Phoenix 100 system [10]. Antimicrobial susceptibility testing of 
A. baumannii was done by the Kirby–Bauer disk diffusion method in 
accordance with the CLSI guidelines 2016 [11].
Gelatinase assay
The isolate was grown in brain heart infusion broth and incubated at 
37°C for 18 h. One loopful of culture was inoculated on to Luria Bertani 
Agar containing gelatin (30 g/L). The plates were incubated overnight 
at 37°C and then cooled for 5 h at 4°C. The positive result was indicated 
by the appearance of a turbid halo around colonies on the medium for 
gelatinase production [5].
Pellicle or air-liquid interface biofilm (ALI) assay
Pellicle assay or ALI assay was performed by inoculating 5 ml of 
Mueller-Hinton (MH) broth taken two in polystyrene tubes with a single 
colony of isolates of A. baumannii with an initial OD 600 to 0.01. The 
tubes were then incubated for 3 days at 25°C or 37°C without shaking. 
Pellicle formation if any; appeared as a white layer at the surface of MH 
broth [7]. The negative control was used by A. baumannii ATCC 19606, 
and positive control of Pseudomonas aeruginosa (PA01) was maintained 
simultaneously.
Statistical analysis
Statistical analysis was performed using SPSS 23.0 version software 
(SPSS Inc., Chicago, IL). Descriptive statistics like frequency (%) were 
used for analysis. Variables were expressed as percentages. All the data 
were expressed as table diagrams.
RESULTS
A total of 42 isolates of A. baumannii; 21 each from ESBL and non-
ESBL producers from DFI were assessed in the study. All the patients 
were typed 2 diabetes mellitus and comorbidities with hypertension, 
nephropathy, neuropathy, retinopathy, and peripheral vascular diseases. 
The age group of these patients ranged from 30 to 80 years, and the 
maximum number of patients was in the age group of 44 to 64 years. 
Male mean age (55.55±10.25) and female mean age (52.56±10.38) 
were male predominant compared to female.
Gelatinase assay
All the isolates were multidrug resistant among ESBL and non-ESBL 
producer in A. baumannii (n=21 each), positive gelatinase producers 
were observed 8/21(38.09%) and 6/21 (28.57%), respectively (Fig. 
1 and Table 1). Gelatinase production was absent in 13/21 (61.90%) 
of ESBL and 15/21 (71.43%) of non-ESBL producers. ESBL producers 
were more gelatinase producers compared to non-ESBL producers.
Pellicle formation or ALI assay
After 24 h of incubation; a thin pellicle began to form at the surface 
of the liquid media; which further grew in thickness and by the end of 
the third day; an opaque and solid structure covered the entire liquid 
surface. 42 A. baumannii from diabetic foot ulcer isolates was visually 
analyzed for pellicle formation, and 16 (38.09%) isolates tested 
positive. Among pellicle forming isolates, ESBL and non-ESBL were 
10/21 (47.61%) and 6/21 (28.57%), respectively (Fig. 2 and Table 2).
DISCUSSION
Nearly 15–25% of type 2 diabetes mellitus patients experience DFI 
during their lifetime. The predominance is more in males compared 
to female patients [12]. DFIs occur mainly due to polymicrobial and 
monomicrobial infections [13]. Multidrug resistance and production of 
ESBL by microbes and their infections are associated with the increased 
length of hospital stay, with higher morbidity, mortality rate, and cost 
burden to the patients. The virulent factors were more in ESBL isolates 
compared to non-ESBL isolates. A. baumannii, considered to be a low-
grade pathogen indeed has many putative virulence factors. It causes 
a significant major problem in immunodeficiency or diabetic patients.
Our study showed gelatinase production by 38.09% ESBL and 28.57% 
non-ESBL isolates of A. baumannii. Surprisingly, none of the earlier 
studies have reported ESBL and non-ESBL types in DFI isolates 
of A. baumannii. Some studies reported gelatinase production in 
A. baumannii, but it is not clear whether specimens/sample were taken 
from the patient with DFI or not. Hence, this study is the first report 
ESBL and non-ESBL production in A. baumannii from DFI patients. 
Fig. 1: Gelatinase production in Acinetobacter baumannii from 
extended-spectrum beta-lactamase producers isolates. DFI: Diabetic 
foot ulcer infection; NC: Negative control (A. baumannii ATCC19606); 
PC: Positive control (PA01=Pseudomonas aeruginosa 01)
Fig. 2: Pellicle formation or air-liquid interface biofilm in 
Acinetobacter baumannii from Extended-spectrum beta-
lactamase producers isolates. PA01: Pseudomonas aeruginosa 01
Table 1: Association of A. baumannii in ESBL isolates among 
pellicle formation and gelatinase production from DFI
Acinetobacter baumannii 
ESBL (n=21)
Present (%) Absent (%)
Pellicle or ALI at 25°C for 3 days 10 (47.61) 11 (52.38)
Pellicle or ALI at 37°C for 3 days 12 (57.14) 9 (42.86)
Both 25°C and 37°C for 3 days 
incubation
10 (47.61) 8 (38.09)
Gelatinase production 8 (38.09) 13 (61.90)
ESBL: Extended-spectrum beta-lactamase, ALI: Air-liquid interface biofilm, 
DFI: Diabetic foot ulcer infection
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Cevahir et al. [14] reported that gelatinase activity occurred in 14% 
A. baumannii infections. Rasha et al. [15] reported 100% gelatinase 
production by A. baumannii isolates.
Pellicle formation assay in our study showed that among 42 
A. baumannii from diabetic foot ulcer isolates; 38.09% pellicle 
forming isolates were found. Pellicle formation at 25°C and 37°C 
in ESBL and non-ESBL each was 47.61% and 28.57%; 57.14% 
and 42.85%, respectively. Similarly, Marti et al. [7] reported 
that pellicle formation at 25°C and 37°C was 35.9% and 12.2%, 
respectively. Another study by Chabane et al. [6] reported pellicle 
formation or air-liquid interface biofilm formation at 25°C at 
30.32% in A. baumannii isolates. Sara et al. [16] reported that the 
A. baumannii group has a higher ability to form pellicle than other 
than A. baumannii and this feature could be connected to the higher 
pathogenic rate of A. baumannii and probably is contributing factor 
to the increased risk of clinical infection. In our study, colistin and 
polymyxin B only effective drug for multidrug-resistant isolates of 
diabetic foot ulcer patients. Similarly, Sadia et al. [17] reported, 
sensitive was 98% colistin and polymyxin B to stop the rapid 
spreading of ESBL producers. A. baumannii has a higher ability to 
form a pellicle or air-liquid interface biofilm than other species, it 
could be connected to the higher colonization rate of patients by 
pathogenic A. baumannii, and probably contribute to the increased 
risk of DFI. The Gelatinase is a proteolytic enzyme that is capable 
of hydrolyzing gelatin, which can traverse the cell membrane 
and hydrolyze collagen in subcutaneous tissues during wound 
infections. It’s linked to inflammation, therefore, to contribute to 
the virulence on a human.
CONCLUSION
Pellicle formation or air-liquid interface biofilm formation and 
gelatinase production by A. baumannii was high in ESBL producers 
compared to non-ESBL producer isolate from DFIs. Virulence factors 
play a significant role in multidrug-resistant A. baumannii infections. 
On that point numerous factors were studied in which the pellicle 
contribution was maximized to the infection from diabetic foot 
ulcers in patients. Understanding, these elements that influence 
the virulence of this organism will help in recognition of these 
pathogenic isolates with high or low potential virulence. Colistin 
and polymyxin B are the only choices of the drug against multidrug-
resistant A. baumannii infection.
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